Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 18, 2013

View Archived Issues

Researchers from the University of California present two novel ROR1-targeting therapies

LY-2928057 dose-dependently increases serum iron levels in vivo

Moberg reports interim data from phase II study of MOB-015 for onychomycosis

BioLineRx reports initial phase II data for BL-8040 in AML

Millennium Pharmaceuticals begins phase I study of TAK-659

arGEN-X reports findings from dose-escalation part of phase Ib study of ARGX-110

Retrophin agrees to acquire Kyalin Biosciences

Evotec and Yale establish DNA repair research collaboration

Chimeric antigen receptor therapy for pediatric ALL targets the TSLPR

Novel BTK inhibitors patented by Pharmascience

Chinese researchers prepare new SGLT2 inhibitors for diabetes

Ares Trading presents novel BACE1 inhibitors for neurodegenerative disorders

Navidea Biopharmaceuticals submits supplemental NDA to FDA for Lymphoseek

Scientists at Phenex Pharmaceuticals disclose new ROR-gamma modulators

AnaptysBio forms antibody development agreement with Momenta Pharmaceuticals

Capricor Therapeutics cleared to begin phase II portion of ALLSTAR trial

Hoffmann-La Roche synthesizes new PDE10A inhibitors for psychotic disorders

Studies in different species reveal developmental role for Lhx6 in schizophrenia

Boehringer Ingelheim patents new GPR40 agonists for diabetes

New NPFF1 receptor antagonists for pain designed by French group

MultiStem receives orphan drug designation in Europe

Novel radioligand described for imaging Abeta in AD

FDA approves Prosigna breast cancer gene signature assay

Ixico offers business update

PIVKA-II test kit for HCC launched in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...